Inclusion Criteria

- INCLUSION CRITERIA:

1. Metastatic cancer that expresses Her-2 at greater than or equal to 2+ and
assessed by immunohistochemistry (IHC) in the clinical laboratory improvement
amendment (CLIA) approved test in the Laboratory of Pathology, Center for Cancer
Research (CCR), National Cancer Institute (NCI), National Institutes of Health
(NIH).

2. Patients must have previously received systemic standard care (or effective
salvage chemotherapy regimens) for metastatic disease, if known to be effective
for that disease, and have been either non-responders (progressive disease) or
have recurred. Subjects with estrogen receptor-positive or progesterone
receptor-positive breast cancer must have progressed on or not be a candidate
for anti-estrogens or aromatase inhibitors and all breast cancer patients must
have progressed on or not be a candidate for an anthracycline-containing regimen
and a taxane-containing regimen.

3. Patients with breast cancer must have previously received trastuzumab. Patients
will not continue to receive trastuzumab during the trial period.

4. Greater than or equal to 18 years of age.

5. Willing to sign a durable power of attorney

6. Able to understand and sign the Informed Consent Document

7. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

8. Life expectancy of greater than three months.

9. Patients of both genders must be willing to practice birth control from the time
of enrollment on this study and for up to four months after receiving the
preparative regimen.

10. Serology:

1. Seronegative for human immunodeficiency virus (HIV) antibody. (The
experimental treatment being evaluated in this protocol depends on an
intact immune system. Patients who are HIV seropositive can have decreased
immune-competence and thus be less responsive to the experimental treatment
and more susceptible to its toxicities.)

2. Seronegative for hepatitis B antigen, and seronegative for hepatitis C
antibody. If hepatitis C antibody test is positive, then patient must be
tested for the presence of antigen by reverse transcriptase polymerase
chain reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA)
negative.

3. Women of child-bearing potential must have a negative pregnancy test
because of the potentially dangerous effects of the preparative
chemotherapy on the fetus.

11. Hematology:

1. Absolute neutrophil count greater than 1000/mm^3 without the support of
filgrastim.

2. White blood cell (WBC) (> 3000/mm^3).

3. Platelet count greater than 100,000/mm^3.

4. Hemoglobin greater than 8.0 g/dl.

12. Chemistry:

1. Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less
or equal to 2.5 times the upper limit of normal.

2. Serum creatinine less than or equal to 1.6 mg/dl.

3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with
Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

13. Left ventricular ejection fraction (LVEF) greater than or equal to 50%.

14. More than four weeks must have elapsed since any prior systemic therapy at the
time the patient receives the preparative regimen, and patients' toxicities must
have recovered to a grade 1 or less (except for toxicities such as alopecia or
vitiligo).

15. Patients who have previously received anti-cytotoxic T-lymphocyte antigen 4
(CTLA4) antibody therapy must have a normal colonoscopy with normal colonic
biopsies.

EXCLUSION CRITERIA

1. Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

2. Active systemic infections; coagulation disorders or other major medical illnesses of
the cardiovascular, respiratory or immune system; myocardial infarction; cardiac
arrhythmias; obstructive or restrictive pulmonary disease.

3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease).

4. Concurrent opportunistic infections (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who have decreased immune
competence may be less responsive to the experimental treatment and more susceptible
to its toxicities).

5. Concurrent Systemic steroid therapy

6. History of severe immediate hypersensitivity reaction to any of the agents used in
this study.

7. History of coronary revascularization or ischemic symptoms

8. Documented forced expiratory volume in 1 second (FEV1) less than or equal to 60%
predicted tested in patients with:

1. A prolonged history of cigarette smoking (20 pack/year of smoking within the
past 2 years).

2. Symptoms of respiratory dysfunction